AIM Vaccine Insider Ups Holding By 27% During Year
AIM Vaccine Insider Ups Holding By 27% During Year
From what we can see, insiders were net buyers in AIM Vaccine Co., Ltd.'s (HKG:6660 ) during the past 12 months. That is, insiders acquired the stock in greater numbers than they sold it.
从我们所见，过去12个月艾美疫苗股份有限公司（HKG:6660）的内部人员净买家。即，内部人员收购的股票数量比贩卖的数量多。
While insider transactions are not the most important thing when it comes to long-term investing, we would consider it foolish to ignore insider transactions altogether.
虽然在长期投资方面内部交易并非最重要的事情，但完全忽略内部交易是愚蠢的。
The Last 12 Months Of Insider Transactions At AIM Vaccine
艾美疫苗内部交易的最近12个月
In the last twelve months, the biggest single purchase by an insider was when Executive Chairman & CEO Yan Zhou bought HK$1.4m worth of shares at a price of HK$6.65 per share. That means that an insider was happy to buy shares at above the current price of HK$6.50. Their view may have changed since then, but at least it shows they felt optimistic at the time. In our view, the price an insider pays for shares is very important. Generally speaking, it catches our eye when an insider has purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price. The only individual insider to buy over the last year was Yan Zhou.
在过去的12个月中，一位内部人员进行了最大的单笔购买，即执行主席兼首席执行官周岩以每股6.65港元的价格购买了140万港元的股份。这意味着内部人员愿意以高于当前每股6.50港元的价格购买股票。尽管他们的观点可能已经改变，但至少表明当时他们感到乐观。在我们看来，内部人员购买股票的价格非常重要。一般来说，当内部人员以高于当前价格购买股票时，我们的注意力会被吸引，因为这表明他们认为即使在更高的价格下这些股票也值得购买。唯一一个在去年购买的内部个人是周岩。
Yan Zhou bought a total of 1.33m shares over the year at an average price of HK$7.86. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
周岩在过去一年内以平均每股7.86港元的价格购买了133万股股票。下面可以看到最近12个月内（按公司和个人）进行的内部交易的视觉呈现。如果您想准确了解谁出售了多少以及何时出售，请单击下面的图表！
There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies that insiders are buying.
还有很多其他的公司，公司的内部人士正在购买股票。你可能不想错过这个免费的小市值公司的低估列表。
Insider Ownership Of AIM Vaccine
艾美疫苗的内部持股
For a common shareholder, it is worth checking how many shares are held by company insiders. We usually like to see fairly high levels of insider ownership. AIM Vaccine insiders own about HK$2.2b worth of shares (which is 28% of the company). Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.
对于普通股东来说，查看公司内部人员持有的股份数量是有价值的。我们通常希望看到相当高水平的内部持股。艾美疫苗内部人员拥有约22亿港元的股份（占公司的28%）。大多数股东都会很高兴看到这种程度的内部持股，因为它表明管理层的激励与其他股东保持良好的一致性。
So What Do The AIM Vaccine Insider Transactions Indicate?
那么，艾美疫苗内部交易的表现如何？
Insider purchases may have been minimal, in the last three months, but there was no selling at all. That said, the purchases were not large. But insiders have shown more of an appetite for the stock, over the last year. It would be great to see more insider buying, but overall it seems like AIM Vaccine insiders are reasonably well aligned (owning significant chunk of the company's shares) and optimistic for the future. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. In terms of investment risks, we've identified 2 warning signs with AIM Vaccine and understanding them should be part of your investment process.
在过去三个月内，内部人员购买股票的数量可能很少，但完全没有卖出。也就是说，购买量并不大。但在过去的一年中，内部人员对该股的投资热情更高。看到更多内部人员购买股票是让人欣慰的，但总的来说，艾美疫苗内部人员持股数量很高（持有公司股份的重要部分），并且看好未来。虽然了解内部人员买卖情况有助于投资决策，但了解公司面临的风险也同样重要。在投资风险方面，我们已经发现艾美疫苗存在2个警示信号，理解它们应该是您投资过程中的一部分。
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
当然，您可能会在其他地方找到一项出色的投资。因此，请查看此免费的有趣公司列表。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
对于本文而言，内部人是指向相关监管机构报告其交易的个人。我们目前仅考虑公开市场交易和直接利益的私人处置，但不包括衍生交易或间接利益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有反馈？对内容感到担忧？请直接与我们联系。或者，发送电子邮件至editorial-team (at) simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论，只使用公正的方法论，我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议，也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意，我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
对本文有反馈？对内容感到担忧？请直接与我们联系。或者，发送电子邮件至editorial-team@simplywallst.com。